Related posts

Stocks flat, Bitcoin risesSanta arrives with a rallyCrypto crumbles as stocks climb
Investor Insights

This summary was created by AI, based on 12 opinions in the last 12 months.

Experts have varying opinions on Amgen Inc. Some are impressed with the recent acquisition and positive future earnings and revenue growth prospects. Others highlight the stock's drop due to competition in weight-loss drugs but still see potential for revenue growth over time. Overall, the stock is seen as a good long-term investment with a wide moat in the healthcare sector.

Consensus
Mixed
Valuation
Fair Value
BUY
Amgen Inc.

His impression was that the Phase 1 trial did go well. Management emphasized long way to go before it would have a monetary impact. Stock did sell off when earnings released. Still likes it. Recent acquisition will be positive for future earnings and revenue growth. Not expensive. Lots in pipeline.

biotechnology / pharmaceutical
HOLD
Amgen Inc.

Drop mainly due to NVO and LLY leading the pack on weight-loss drugs. Still, AMGN has a great lineup of drugs, revenues should grow over time. Ranks well for him. More beta than a normal healthcare stock. Now at 100-day MA, almost oversold. Makes sense from an earnings growth perspective, high single digits. Fine name, he just prefers others.

biotechnology / pharmaceutical
BUY
Amgen Inc.

Down a bit on earnings report this morning, but overlook that, short-term reaction. Phase 1 weight-loss drug primed to compete with LLY's, though not yet being promoted as its next blockbuster. Much more modest multiple than LLY.

biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Jan 11/23, Up 16%)

Reasonable multiple, mid-high teens. Good growth rate, highly predictable. Has a GLP-1 candidate, good results in Phase 1 testing. 17% of revenue goes back into R&D.

biotechnology / pharmaceutical
PARTIAL BUY
Amgen Inc.

It reports Tuesday If Eli Lilly reports 9also Tuesday) good GLP numbers, he'd buy Amgen.

biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Aug 08/23, Up 17%)

One of those you just buy today and hold. Pretty volatile. Secular trend in healthcare. Wide moat. 30% free cashflow. Good stock.

biotechnology / pharmaceutical
BUY
Amgen Inc.
A big gainer in Q3

They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.

biotechnology / pharmaceutical
BUY
Amgen Inc.

His choice in the biotech space.

biotechnology / pharmaceutical
BUY
Amgen Inc.

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

biotechnology / pharmaceutical
TOP PICK
Amgen Inc.

A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech

(Analysts’ price target is $256.05)
biotechnology / pharmaceutical
BUY
Amgen Inc.

He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.

biotechnology / pharmaceutical
HOLD
Amgen Inc.

Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors. 

biotechnology / pharmaceutical
TOP PICK
Amgen Inc.
Granddaddy of biotech. Even better than it used to be. Very deep bench of drugs. New acquisition will add growth on top of already-decent growth. Very strong financials. Income opportunity, stability, and some growth not yet fully priced in. Yield is 3.14%, well covered at 42%, increased by 11% average annually over 5 years. (Analysts’ price target is $268.80)
biotechnology / pharmaceutical
BUY
Amgen Inc.
Share have given up a lot since its Horizon Therapeutics deal, making it an opportunity.
biotechnology / pharmaceutical
BUY
Amgen Inc.
Today, they said they are buying Horizon Therapeutics for $27.8 billion. This deal should close quickly, since there's little overlap of these companies' drugs. Initially, he thought the price was high, but now he likes the deal. An established, big biotech that bought a younger biotech with exciting drugs at a 15% premium. Amgen wants HT's portfolio of drugs treating rare diseases and well-covered by insurance, therefore lucrative. HT's drugs will benefit from Amgen's worldwide distribution.
biotechnology / pharmaceutical
Showing 1 to 15 of 129 entries

Amgen Inc.(AMGN-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 11

Stockchase rating for Amgen Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Amgen Inc.(AMGN-Q) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q

Is Amgen Inc. a buy or a sell?

In the last year, 11 stock analysts published opinions about AMGN-Q. 9 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Amgen Inc. worth watching?

11 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2024-03-28, Amgen Inc. (AMGN-Q) stock closed at a price of $284.21.